Eiger to Participate in Piper Jaffray Healthcare Conference

PALO ALTO, Calif., November 19, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 at 4:00 PM ET at Lotte NY Palace Hotel in New York City.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab.  A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will also host one-on-one meetings with investors.

About Eiger
Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted therapies for rare and ultra-rare diseases.  Our lead program is advancing Lonafarnib into a Phase 3, single pivotal trial to treat Hepatitis Delta Virus (HDV) Infection, initiating in 2018.  Eiger is preparing an NDA for Lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) with plans to file in 2019.  For additional information about Eiger, please visit www.eigerbio.com.

Eiger BioPharmaceuticals

SOURCE Eiger BioPharmaceuticals, Inc.
Investors: Ingrid Choong, PhD
Email: ichoong@eigerbio.com
Phone: 1-650-619-6115

PDF Icon

See More Press Releases

2018-11-21T11:28:38+00:00